Home
MRUS
MRUS News

Latest Merus N.V. (MRUS) News on July 1, 2025

Why Merus N.V. (MRUS) Crashed On Wednesday

Insider Monkey

a month ago

Why Merus N.V. (MRUS) Crashed On Wednesday

MT Newswires

a month ago

Sector Update: Health Care Stocks Mixed Premarket Wednesday

MT Newswires

a month ago

Merus Prices $300 Million Stock Offering

Merus N.V. Announces Pricing of Public Offering of Common Shares

GlobeNewswire

a month ago

Merus N.V. Announces Pricing of Public Offering of Common Shares

MT Newswires

a month ago

Merus Plans Public Share Offering

Merus N.V. Announces Proposed Public Offering of Common Shares

GlobeNewswire

a month ago

Merus N.V. Announces Proposed Public Offering of Common Shares

ASCO 2025: Merus wins in head-to-head with Bicara for head and neck cancer

Clinical Trials Arena

a month ago

ASCO 2025: Merus wins in head-to-head with Bicara for head and neck cancer

Merus to Present at Upcoming Investor Conferences

GlobeNewswire

a month ago

Merus to Present at Upcoming Investor Conferences

BofA Maintains Buy Rating on Merus (MRUS), Lifts PT

Insider Monkey

a month ago

BofA Maintains Buy Rating on Merus (MRUS), Lifts PT

Merus (MRUS) Price Target Raised at BMO After Positive Phase 2 Data

Insider Monkey

a month ago

Merus (MRUS) Price Target Raised at BMO After Positive Phase 2 Data

Merus updates on Petosemtamab+Pembrolizumab data in HNSCC

TipRanks

a month ago

Merus updates on Petosemtamab+Pembrolizumab data in HNSCC

MT Newswires

a month ago

Top Midday Gainers

MT Newswires

a month ago

Update: Merus Shares Surge After Revealing Favorable Interim Cancer Trial Data

MT Newswires

a month ago

Merus' Cancer Treatment Delivers 'Flawless Victory' in Phase 2 Update, Truist Says

Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics

Investor's Business Daily

a month ago

Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics

MT Newswires

a month ago

Sector Update: Health Care

MT Newswires

a month ago

Merus Says Interim Cancer Trial Data Show 'Robust' Efficacy, Durability; Shares Jump Premarket

Merus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC

GlobeNewswire

a month ago

Merus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC

Merus Announces the Journal Publication of Petosemtamab Mechanism of Action

GlobeNewswire

2 months ago

Merus Announces the Journal Publication of Petosemtamab Mechanism of Action

Merus First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

2 months ago

Merus First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Merus N.V. (MRUS): Among the Best Cancer Stocks to Invest in for Long-Term Gain

Insider Monkey

2 months ago

Merus N.V. (MRUS): Among the Best Cancer Stocks to Invest in for Long-Term Gain

Merus to Present at BofA Securities 2025 Health Care Conference

GlobeNewswire

2 months ago

Merus to Present at BofA Securities 2025 Health Care Conference

Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates

Zacks

2 months ago

Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates

Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update

GlobeNewswire

2 months ago

Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update

Earnings Preview: Merus N.V. (MRUS) Q1 Earnings Expected to Decline

Zacks

2 months ago

Earnings Preview: Merus N.V. (MRUS) Q1 Earnings Expected to Decline

Merus Will Have a Best-in-Class Treatment for Head and Neck Cancer, Analysts Say

Barrons.com

2 months ago

Merus Will Have a Best-in-Class Treatment for Head and Neck Cancer, Analysts Say

Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting

GlobeNewswire

2 months ago

Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting

Is Merus (NASDAQ:MRUS) the Best High Short Interest Stock to Buy Now?

Insider Monkey

2 months ago

Is Merus (NASDAQ:MRUS) the Best High Short Interest Stock to Buy Now?

Strength Seen in BioMarin (BMRN): Can Its 6.3% Jump Turn into More Strength?

Zacks

3 months ago

Strength Seen in BioMarin (BMRN): Can Its 6.3% Jump Turn into More Strength?

Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

GlobeNewswire

3 months ago

Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

Analyst Forecasts Just Became More Bearish On Merus N.V. (NASDAQ:MRUS)

Simply Wall St.

4 months ago

Analyst Forecasts Just Became More Bearish On Merus N.V. (NASDAQ:MRUS)

Merus N.V. (MRUS) Reports Q4 Loss, Lags Revenue Estimates

Zacks

4 months ago

Merus N.V. (MRUS) Reports Q4 Loss, Lags Revenue Estimates

Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update

GlobeNewswire

4 months ago

Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update

Merus to Present at Upcoming Investor Conferences

GlobeNewswire

4 months ago

Merus to Present at Upcoming Investor Conferences

Will Iovance Biotherapeutics (IOVA) Report Negative Earnings Next Week? What You Should Know

Zacks

4 months ago

Will Iovance Biotherapeutics (IOVA) Report Negative Earnings Next Week? What You Should Know

MT Newswires

4 months ago

Merus Says US FDA Grants Breakthrough Therapy Designation to Petosemtamab

Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma

GlobeNewswire

4 months ago

Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma

Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit

GlobeNewswire

5 months ago

Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit

MT Newswires

5 months ago

Piper Sandler Initiates Merus at Overweight With $84 Price Target

MT Newswires

5 months ago

Wells Fargo Initiates Merus at Overweight With $91 Price Target

New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer

GlobeNewswire

5 months ago

New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus N.V. (MRUS): The Biotech Stock with Biggest Upside Potential

Insider Monkey

5 months ago

Merus N.V. (MRUS): The Biotech Stock with Biggest Upside Potential

Companies Like Merus (NASDAQ:MRUS) Are In A Position To Invest In Growth

Simply Wall St.

6 months ago

Companies Like Merus (NASDAQ:MRUS) Are In A Position To Invest In Growth

MT Newswires

6 months ago

Merus, Biohaven Partner to Develop Bispecific Therapies for Cancers

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

GlobeNewswire

6 months ago

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

Jim Cramer Says Merus (MRUS) Still ‘Very Speculative’

Insider Monkey

6 months ago

Jim Cramer Says Merus (MRUS) Still ‘Very Speculative’

MT Newswires

6 months ago

Merus Reports First Person Dosed in Mid-Stage Petosemtamab Trial

Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC

GlobeNewswire

6 months ago

Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC

Merus (MRUS): FDA Approval and Speculative Future in Cancer Therapy

Insider Monkey

7 months ago

Merus (MRUS): FDA Approval and Speculative Future in Cancer Therapy

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

GlobeNewswire

7 months ago

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus Scores Its First FDA Approval For Lung Cancer Drug

Benzinga

7 months ago

Merus Scores Its First FDA Approval For Lung Cancer Drug

Merus’ Bizengri granted FDA accelerated approval to treat NRG1+ cancers

Clinical Trials Arena

7 months ago

Merus’ Bizengri granted FDA accelerated approval to treat NRG1+ cancers

MT Newswires

7 months ago

Merus Gets US FDA Approval for Bizengri in Advanced Pancreatic, Lung Cancers

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

GlobeNewswire

7 months ago

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus price target lowered to $109 from $111 at Guggenheim

TipRanks

7 months ago

Merus price target lowered to $109 from $111 at Guggenheim

Merus Licenses US Commercialization Rights For Cancer Potential Zenocutuzumab, Analyst Highlight Merus' Pipeline

Benzinga

7 months ago

Merus Licenses US Commercialization Rights For Cancer Potential Zenocutuzumab, Analyst Highlight Merus' Pipeline

MT Newswires

7 months ago

Merus Licenses Potential Lung, Pancreatic Cancer Treatment to Partner Therapeutics

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

GlobeNewswire

7 months ago

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

GlobeNewswire

7 months ago

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus NV (MRUS): Among the Most Promising Cancer Stocks According to Hedge Funds

Insider Monkey

7 months ago

Merus NV (MRUS): Among the Most Promising Cancer Stocks According to Hedge Funds

PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...

GuruFocus.com

8 months ago

PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...

Is Merus N.V. (MRUS) Top Performing European Stock Heading into 2025?

Insider Monkey

8 months ago

Is Merus N.V. (MRUS) Top Performing European Stock Heading into 2025?

Merus to Present at Upcoming Investor Conferences

GlobeNewswire

8 months ago

Merus to Present at Upcoming Investor Conferences

MT Newswires

8 months ago

Merus Gets FDA Extension on Prescription Drug User Fee Act Goal Date for Zenocutuzumab to Feb. 4

Merus Receives FDA extension of PDUFA for zenocutuzumab

GlobeNewswire

8 months ago

Merus Receives FDA extension of PDUFA for zenocutuzumab

Merus Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

8 months ago

Merus Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

MT Newswires

8 months ago

Merus's Shares Dip After Reporting Wider-Than-Expected Q3 Net Loss

Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates

Zacks

8 months ago

Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates

Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update

GlobeNewswire

8 months ago

Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update

MT Newswires

8 months ago

UBS Initiates Merus With Buy Rating, $72 Price Target

Investing in Merus (NASDAQ:MRUS) five years ago would have delivered you a 227% gain

Simply Wall St.

8 months ago

Investing in Merus (NASDAQ:MRUS) five years ago would have delivered you a 227% gain

MeiraGTx (MGTX) Surges 14.9%: Is This an Indication of Further Gains?

Zacks

8 months ago

MeiraGTx (MGTX) Surges 14.9%: Is This an Indication of Further Gains?

Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC

GlobeNewswire

9 months ago

Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC

TimesSquare Capital Management U.S. Small Cap Growth Strategy Established a Position in Merus N.V. (MRUS)

Insider Monkey

9 months ago

TimesSquare Capital Management U.S. Small Cap Growth Strategy Established a Position in Merus N.V. (MRUS)

Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024

GlobeNewswire

9 months ago

Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024

Merus NV (MRUS): Short Seller Sentiment is Bearish on This Cancer Stock

Insider Monkey

10 months ago

Merus NV (MRUS): Short Seller Sentiment is Bearish on This Cancer Stock

Merus NV (MRUS): Top ADR Stock According to Hedge Funds

Insider Monkey

10 months ago

Merus NV (MRUS): Top ADR Stock According to Hedge Funds

MT Newswires

10 months ago

Merus Insider Sold Shares Worth $270,000, According to a Recent SEC Filing

We're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn Rate

Simply Wall St.

a year ago

We're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn Rate

Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference

GlobeNewswire

a year ago

Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference

Merus N.V. (MRUS) Reports Q2 Loss, Lags Revenue Estimates

Zacks

a year ago

Merus N.V. (MRUS) Reports Q2 Loss, Lags Revenue Estimates

Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update

GlobeNewswire

a year ago

Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update

Agenus (AGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Zacks

a year ago

Agenus (AGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks

a year ago

Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC

GlobeNewswire

a year ago

Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC

Institutional investors control 69% of Merus N.V. (NASDAQ:MRUS) and were rewarded last week after stock increased 5.5%

Simply Wall St.

a year ago

Institutional investors control 69% of Merus N.V. (NASDAQ:MRUS) and were rewarded last week after stock increased 5.5%

MT Newswires

a year ago

Merus Begins Phase 2 Trial of Colorectal Cancer Drug Candidate

Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC

GlobeNewswire

a year ago

Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC

MT Newswires

a year ago

Sector Update: Health Care Stocks Retreat Late Afternoon

MT Newswires

a year ago

Merus Names New Chief Medical Officer

Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer

GlobeNewswire

a year ago

Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer

MT Newswires

a year ago

Stifel Nicolaus Adjusts Merus N.V Price Target to $99 From $90, Maintains Buy Rating

MT Newswires

a year ago

Merus Insider Sold Shares Worth $475,456, According to a Recent SEC Filing

MT Newswires

a year ago

BMO Capital Raises Price Target on Merus to $91 From $84, Maintains Outperform Rating

MT Newswires

a year ago

Canaccord Genuity Adjusts Price Target on Merus to $67 From $54, Maintains Buy Rating

MT Newswires

a year ago

Merus Says Target Tumors in Lung Cancer Patients Decrease in Size After MCLA-129 Treatment

Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting

GlobeNewswire

a year ago

Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting

MT Newswires

a year ago

Truist Securities Raises Price Target on Merus to $88 From $69, Maintains Buy Rating

Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting

GlobeNewswire

a year ago

Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting

MT Newswires

a year ago

Merus Prices $400.2 Million Public Share Offering

Share on Social Networks: